Give the prompt to Orris app jo clinical based app 1)what is the need for study 2)what is the use of study 3)how can introduce to CRC about my topic 4)rational should be explained so that CRC member understand that study 5)my objectives primary and secondary objective why i choose this objectives 6)explaining the methodology step wise so they can understand 7) my performa signify my study And other points which you feel relvanat that can be asked in CRC and it can create problems for me to give the answer 8)and also tell about my review literatures and they also signify that study should be conducted

Reading File

Running Command

cd /tmp/workspace/attachments/1cedfcc6-b17e-4656-afe7-377f32731f47/ && python3 -c " from pptx import Presentation prs = Presentation('ANUJ_final.pptx') for i, slide in enumerate(prs.slides, 1): print(f'=== SLIDE {i} ===') for shape in slide.shapes: if shape.has_text_frame and shape.text_frame.text.strip(): print(shape.text_frame.text) print() "

Searching PubMed

leprosy disability WHO grading epidemiology India

Searching the Web

CRC committee questions leprosy disability study thesis protocol India common pitfalls

I now have all the information I need from the presentation. Let me compile a comprehensive, thorough CRC presentation guide for Dr. Anuj Jain.

CRC Presentation Guide for Dr. Anuj Jain

Study Title: Clinico-Epidemiological Correlation of Disability Among Newly Diagnosed Leprosy Patients: A Cross-Sectional Study at a Tertiary Care Centre in Moradabad

1. NEED FOR THE STUDY (Why this study must be done?)

Prepare the following points clearly:

Global & National Burden:

Leprosy remains a notifiable disease in India, which still contributes the highest number of new cases globally (approximately 60% of world's new cases annually as per WHO Global Leprosy Update).
Despite MDT achieving prevalence below 1/10,000 at national level, new case detection rates remain high, indicating ongoing active transmission.
India reported over 1 lakh new cases per year in recent years - disability at detection is a key indicator of programme performance.

Problem of Disability Specifically:

Disability in leprosy is not just a medical problem but a social, economic, and human rights issue - it leads to stigma, loss of livelihood, and exclusion.
Grade 2 disability at the time of diagnosis indicates late presentation and failure of early detection efforts.
Disability among newly diagnosed patients is a WHO indicator for leprosy programme quality - the higher the proportion, the worse the early detection effort.

Regional Gap:

Moradabad, UP is in an endemic belt for leprosy in India. Uttar Pradesh consistently reports among the highest new case detection rates nationally.
No published data exists specifically from Moradabad/Western UP documenting the clinico-epidemiological profile of disability at diagnosis.
Studies from other parts of India (West Bengal, Rajasthan, Central India, Northeast India) show widely varying disability rates from 6.4% to 43.75% - you cannot extrapolate these to your region without local data.

2. USE OF THE STUDY (What will come out of it?)

Answer confidently:

The findings will provide local, region-specific prevalence data on Grade 1 and Grade 2 disability at diagnosis - which is currently absent.
It will identify which clinical types of leprosy (e.g., BT, BL, LL) and which nerve involvements most commonly lead to disability - helping clinicians prioritize nerve function assessment.
It will identify sociodemographic predictors (age, sex, occupation, literacy, delay in diagnosis) - enabling targeted awareness and outreach programmes.
Data on lepra reactions and their role in disability will help in early reaction management protocols.
This data can feed into the State NLEP (National Leprosy Eradication Programme) to plan district-level disability prevention strategies.
It will serve as a baseline dataset for future intervention studies or longitudinal follow-up.

3. HOW TO INTRODUCE YOUR TOPIC TO CRC

Follow this logical narrative structure when speaking:

"Leprosy is caused by Mycobacterium leprae and is a leading cause of preventable peripheral neuropathy and disability worldwide. Despite the success of MDT in reducing prevalence, disability at the time of diagnosis remains a significant concern because it reflects late presentation and delays in the programme. WHO uses the proportion of Grade 2 disability among new cases as a key programme indicator. India still bears the highest global burden of new cases, and Uttar Pradesh is one of the most endemic states. Moradabad lies in this endemic zone, yet no study from this region has documented the disability profile and its clinico-epidemiological correlates in newly diagnosed patients. This is the gap our study addresses."

Keep this to under 3-4 minutes. Speak slowly and clearly.

4. RATIONALE (Explain so CRC understands WHY this specific study is needed)

Your rationale slide already mentions this well - but speak it out in layers:

Layer 1 - Problem exists: Leprosy causes preventable nerve damage and disability. Grade 1 = sensory loss (still reversible if caught early). Grade 2 = irreversible visible deformity. Preventing Grade 1 from progressing to Grade 2 saves the patient from lifelong disability.

Layer 2 - Data variability: Indian studies show extreme variation in disability rates (6.4% - 43.75% for Grade 2 alone). This variation is real and is due to geographic, socioeconomic, and healthcare access differences between regions. You cannot apply a West Bengal study's numbers to Moradabad.

Layer 3 - Local data gap: No study has been done at TMMC & RC or the Moradabad region. Your institution's catchment area likely has a specific epidemiological profile - rural patients, manual laborers, delayed healthcare-seeking - which needs to be captured locally.

Layer 4 - Programme relevance: The NLEP needs region-specific data to plan prevention. Without local data, programme resources cannot be efficiently allocated.

One line summary for CRC: "The rationale is that disability rates in leprosy vary widely across India, local data from Moradabad is absent, and without region-specific data we cannot plan effective disability prevention for our population."

5. OBJECTIVES - WHY YOU CHOSE THEM

Primary Objective:

"To determine the proportion of Grade 1 and Grade 2 disability among newly diagnosed leprosy patients using WHO Disability Grading System (1998)."

Why this objective?

Proportion of disability at diagnosis is the standard WHO indicator for leprosy programme performance.
It is simple, reproducible, and directly answers: "How bad is the disability burden at first presentation in our setting?"
It requires no laboratory cost - only clinical examination.
It forms the denominator and benchmark for all secondary analyses.

Secondary Objectives - Why each one?

Association with clinical type (Ridley-Jopling + PB/MB):

Multibacillary types (BL, LL) are biologically more likely to cause nerve damage than PB types. You want to confirm if this holds true in your cohort and quantify the risk.
Ridley-Jopling gives more granular classification than just PB/MB.

Association with sociodemographic factors and delay in diagnosis:

Delay in diagnosis = the single most modifiable factor leading to disability. If you can quantify how many months of delay lead to disability, it gives a targetable intervention point.
Sociodemographic factors (manual laborers, illiterate patients, males) have been shown to have higher disability in other studies - confirming this locally helps target outreach.

Lepra reactions and disability:

Lepra reactions (Type 1 and Type 2) are the primary mechanism through which acute nerve damage occurs, leading to disability. Studying their occurrence and association with disability grade in newly diagnosed patients is both pathophysiologically sound and clinically important.

6. METHODOLOGY - STEP-WISE FOR CRC

Step 1 - Study Setting

TMMC & RC, Moradabad - a tertiary care centre serving a large catchment from Western UP, which is an endemic zone for leprosy.

Step 2 - Study Design

Observational Cross-Sectional Study - You are measuring the disability status at a single point in time (at diagnosis). This is the appropriate design to answer "What is the proportion of disability at diagnosis?"

If asked why cross-sectional and not cohort: Because your objective is to find prevalence (not incidence or change over time). A cohort would be needed if you were following patients after treatment, which is a different question.

Step 3 - Study Period

18 months after CRC + IEC approval.

Step 4 - Data Source

All newly diagnosed leprosy patients attending DVL OPD/IPD at TMMC & RC during the study period.

Step 5 - Sampling

Convenient (consecutive) sampling - all eligible new leprosy patients fulfilling inclusion criteria during the study period will be enrolled. This is appropriate for a cross-sectional prevalence study at a single centre.

Step 6 - Sample Size

N = 156, calculated using:

Formula: N = Z²α × P(100-P) / E²

P = 11.5% (from Sarkar et al., IJDVL 2012, West Bengal - disability prevalence among new cases)

Zα = 1.96 (95% CI), E = 5%

Adding 10-15% non-response, enrol approximately 175 patients.

If asked: Why use P=11.5%? This is from the most methodologically similar Indian study (institution-based, tertiary care, new leprosy patients). Other higher rates came from mass-screening or field-based studies, which are not comparable to your OPD-based study.

Step 7 - Patient Selection (Inclusion/Exclusion)

Speak through each criterion and why it exists:

Age 18-65: Excludes pediatric leprosy (different clinical profile, separate epidemiology, requires different consent) and extreme elderly who may have disability from other causes.
Newly diagnosed, not on MDT: Ensures you are capturing disability at presentation, not disability caused or modified by treatment.
Excluding relapse cases: Relapses have a different immunological profile; mixing them would confound results.
Excluding other causes of disability (DM, CVA, trauma): To ensure disability is attributable to leprosy only - this maintains internal validity.
Excluding pregnant/lactating females: Pregnancy alters immunity and nerve function; it could confound disability assessment.

Step 8 - Data Collection (Proforma/CRF)

Your Case Record Form covers: Demographics → History (delay in diagnosis, symptoms onset) → Clinical classification (Ridley-Jopling + PB/MB) → Nerve examination (thickening, tenderness) → Sensory & Motor Nerve Function Impairment → WHO Disability Grading → Type of Deformity → Investigations.

Every field directly maps to an objective. Be ready to say this if asked.

Step 9 - WHO Disability Grading System (1998)

Grade 0 = no disability, no anaesthesia Grade 1 = loss of protective sensation (eyes, hands, feet), no visible deformity Grade 2 = visible deformity or damage (lagophthalmos, corneal opacity, claw hand, foot drop, ulcers, etc.)

Assessed separately for eyes, hands, and feet. The highest grade among the three body regions is the final patient grade.

Step 10 - Statistical Analysis

Descriptive: Mean ± SD for continuous variables, frequency/percentage for categorical
Inferential: Chi-square / Fisher's exact test for associations; Binary logistic regression for independent predictors (expressed as AOR with 95% CI); ANOVA/t-test for continuous comparisons
Software: SPSS; significance at p < 0.05

7. HOW YOUR PROFORMA SIGNIFIES THE STUDY

Be prepared to walk through the CRF section by section:

Proforma Section	Objective it Serves
A. Demographic Details (age, sex, occupation, literacy, address)	Secondary objective - sociodemographic association
B. History (duration of symptoms, delay in diagnosis, previous treatment)	Secondary objective - delay in diagnosis association
C. Clinical Classification (Ridley-Jopling, PB/MB)	Primary + Secondary objective 1
D. Nerve Examination (thickening, tenderness of ulnar, median, radial cutaneous, common peroneal, posterior tibial, facial, great auricular)	Primary + Secondary objective 1
E. Sensory & Motor NFI (monofilament testing, grip/pinch strength, foot/wrist drop assessment)	Primary objective - determining Grade 1
F. WHO Disability Grading (0/1/2) for eyes/hands/feet	Primary objective - direct measurement variable
G. Type of Deformity (claw hand, foot drop, lagophthalmos, etc.)	Primary + Secondary objective 1
H. Investigations (slit skin smear, biopsy if needed)	Clinical classification confirmation

Key message to CRC: "Every data field in the proforma is linked to a specific objective. There are no redundant fields, and no objective is without a corresponding data field."

8. REVIEW OF LITERATURE - HOW IT SUPPORTS THE STUDY

Walk through your 5 key references and what each one contributes:

1. Sarkar J et al., IJDVL 2012 (West Bengal) - [reference used for sample size]

Institution-based study, tertiary care centre, new leprosy patients in endemic district
Grade 2 disability: 11.5% - used as P value in your sample size formula
Found association with MB type, nerve thickening, delay in treatment
Gap: West Bengal data, not from UP/Moradabad

2. Ishore K et al., Indian J Lepr 2019 (West Bengal)

Sub-district level study, Darjeeling, West Bengal
Reported Grade 2 disability rate and associated factors
Found male sex, manual occupation, and delay as significant predictors
Gap: Different geographic setting, community-based, not tertiary care

3. Rathod SP et al., An Bras Dermatol 2020 (Rajasthan)

Retrospective analysis of institutional records
Found higher Grade 2 disability rates in MB leprosy and in those with delayed diagnosis
Gap: Retrospective design, different state

4. Shravani B et al., J Fam Med Prim Care 2022 (Central India)

Pilot study from endemic area - reported Grade 2 disability rates
Found sociodemographic correlates
Gap: Pilot study, small sample, Central India

5. Laldinthari C et al., Asian J Med Sci 2023 (Northeast India)

Clinical profile of new leprosy patients with deformities - Northeast India data
Gap: Entirely different regional epidemiology

Synthesis statement: "All existing Indian studies are from West Bengal, Rajasthan, Central India, or Northeast India. None are from Uttar Pradesh, and specifically none from Moradabad. The disability rates vary from 6.4% to 43.75%, which proves the regional heterogeneity of this problem. This is exactly why a local study from our tertiary care centre is needed."

9. ANTICIPATED TOUGH CRC QUESTIONS - AND HOW TO ANSWER THEM

Q1: "Why cross-sectional? Why not a cohort study to see how disability progresses?"

Answer: Our objectives are to assess the burden and correlates of disability at the time of diagnosis - this is a prevalence question, and cross-sectional design is the gold standard for it. A cohort design would be needed to study progression after treatment, which is a separate research question. Cross-sectional design is also feasible within the MD tenure of 3 years, while a cohort study would take significantly longer.

Q2: "Your sample size is only 156. Is that enough?"

Answer: The sample size is calculated at 95% confidence interval with 5% absolute precision using a published Indian institutional study (P=11.5%). Adding 10-15% for non-response gives approximately 175 patients. Given that TMMC & RC is a tertiary centre in an endemic zone, 18 months of enrollment is expected to yield more than this number. The sample size is statistically valid for estimating prevalence.

Q3: "Why did you use P=11.5% from West Bengal when you expect the rate may be different in Moradabad?"

Answer: The P value should come from the most methodologically similar study - institution-based, tertiary care, new cases. Sarkar et al. 2012 is the closest match. If the true rate in our population is higher, our sample size would still be adequate (as P=50% gives the maximum sample size for a given precision - using P=11.5% gives a conservative but valid estimate for this design). Using a higher P would only increase sample size, which would make enrollment harder, not easier.

Q4: "You have excluded patients under 18. What about pediatric leprosy? Don't children also get disability?"

Answer: Pediatric leprosy is a separate clinical and epidemiological entity requiring specific consent protocols (assent + parental consent), and the nerve function assessment tools used for adults (monofilament testing grades, grip strength norms) are not validated for children below 15 years. Including them would introduce measurement heterogeneity. A separate dedicated pediatric study would be more appropriate.

Q5: "You are excluding pregnant and lactating women. Isn't this creating a selection bias?"

Answer: Pregnancy is associated with altered immunological status and can cause type 1 lepra reactions independently, which may affect nerve function and hence disability grading. Including pregnant women would confound the association between clinical type and disability. Excluding them follows the precedent of similar published studies (Shravani et al. 2022, Sarkar et al. 2012). The number of pregnant/lactating leprosy patients expected in our cohort is small, so the impact on generalizability is minimal.

Q6: "How will you assess sensory nerve function? Is the method standardized?"

Answer: Sensory NFI will be assessed using Semmes-Weinstein monofilament testing (standard tool per WHO and Van Brakel 2000 guidelines) - 10g monofilament for hands and feet, and corneal touch sensation for eyes. Motor NFI assessed by voluntary muscle testing (VMT) for grip, pinch, foot dorsiflexion, eyelid closure. These are the WHO-recommended validated methods for leprosy nerve function assessment.

Q7: "How will you ensure inter-observer reliability in disability grading?"

Answer: All patients will be examined by a single trained examiner (the PI) using a standardized protocol. Sensory testing will follow the WHO/ILEP nerve function impairment guidelines. If a senior resident or guide confirms grading in doubtful cases, a note will be made. Since this is a single-centre study with a single principal investigator, inter-observer variability is minimized by design.

Q8: "You mention 'delay in diagnosis' in your objectives. How will you measure this?"

Answer: Delay in diagnosis is defined as the time from the onset of first symptom (patch, numbness, loss of sensation - as reported by the patient) to the date of confirmed diagnosis/registration at TMMC & RC. This will be recorded in months, as self-reported history. While recall bias exists, this is the standard approach used in all referenced studies for delay in diagnosis measurement.

Q9: "What ethical concerns does this study have?"

Answer: This is an observational study with no intervention - patients are only examined, not given any additional treatment or procedure beyond standard clinical care. All data will be recorded after informed consent in English and Hindi (bilingual consent form is part of the proforma). Patient identity will be de-identified in the dataset. No photographs of identifiable body parts will be taken without additional consent. The study involves no additional investigations beyond routine clinical work-up.

Q10: "What is the clinical significance of finding out the disability proportion? How will it help patients?"

Answer: Knowing the local disability burden will:

Identify patients who need immediate rehabilitation referral (Grade 2)
Identify Grade 1 patients who need urgent nerve function monitoring to prevent progression
Help NLEP plan self-care education, MCR footwear distribution, and physiotherapy referral in our region
Influence how our department counsels newly diagnosed patients
Generate publication-quality data that can be shared with district health officers for programme planning

Q11: "Your study is at a tertiary care centre - will your results be representative of the community?"

Answer: This is a valid limitation that you must proactively acknowledge. Tertiary care centres tend to see more severe/delayed cases, so our disability rates may be higher than community rates. We will acknowledge this in limitations. However, the study is not trying to estimate community prevalence - it is studying the profile of patients presenting to tertiary care, which itself is valid and clinically meaningful for how our department should be organized and how these patients should be managed.

Q12: "Why did you not include an EHF (Eye-Hand-Foot) score instead of just WHO Disability Grade?"

Answer: The WHO Disability Grading (0/1/2) is the standard outcome indicator used by NLEP and WHO for programme monitoring, and all comparison studies use this grading. The EHF score (Eye-Hand-Foot) is a more detailed grading giving a score of 0-12, but it is less commonly reported in the Indian literature, making comparison with existing studies difficult. If time permits, EHF score will be recorded as an additional variable.

10. ADDITIONAL POINTS TO PREPARE

On your literature review structure: CRC may ask if you have a comprehensive review. You have 5-6 references on your slides - be ready to say:

You have reviewed studies spanning 2000-2023 (Van Brakel 2000 to Laldinthari 2023)
Studies from multiple Indian states and international literature
The review clearly shows the regional data gap that your study fills

On Ridley-Jopling classification: Know all 5 types - TT, BT, BB, BL, LL - and which are PB (TT, BT) vs MB (BB, BL, LL). Know that disability rate increases from TT to LL end of spectrum.

On type of leprosy prevalent in your region: UP is hyperendemic - multibacillary leprosy and BT types are common. Be ready to discuss this.

On WHO Disability Grading (1998): Know that this is the revision from the older 1970s grading. The 1998 revision added Grade 1 for eyes (corneal anaesthesia), not just Grade 2.

On MDT: Know that PB leprosy = 6 months MDT, MB leprosy = 12 months MDT as per current NLEP/WHO guidelines (though WHO changed to uniform MDT - be ready to discuss this if asked).

On nerve function impairment: Be ready to name all 7 commonly affected nerves: Ulnar, Median, Radial Cutaneous (hand), Common Peroneal, Posterior Tibial (foot), Facial, Great Auricular.

Summary One-Liner for Each Point

CRC Question	Your Core Answer
Why do this study?	No local data from Moradabad in an endemic zone; disability rates vary across India and can't be extrapolated
What will it give?	Local disability prevalence, risk factors, and data for NLEP programme planning
Why cross-sectional?	Prevalence question = cross-sectional is correct; feasible within MD tenure
Why N=156?	Calculated at 95% CI, P=11.5% from closest comparable study, statistically valid
Why these objectives?	Each objective targets a modifiable factor or a WHO programme indicator
Ethical concern?	Observational only, no intervention, bilingual consent, data de-identified
Main limitation?	Tertiary care bias; will be acknowledged in the paper

Best of luck for your CRC presentation, Dr. Anuj. Your protocol is well-structured - the main thing is to speak fluently through the rationale and be ready for the sample size and design questions, as those are the most commonly challenged areas in CRC for cross-sectional studies.

This is a shared conversation. Sign in to Orris to start your own chat.